8.52
price down icon1.05%   -0.09
after-market 시간 외 거래: 8.56 0.04 +0.47%
loading

Biocryst Pharmaceuticals Inc 주식(BCRX)의 최신 뉴스

pulisher
Jul 21, 2025

Is BioCryst Pharmaceuticals Inc. a good long term investmentAccelerated financial growth - Autocar Professional

Jul 21, 2025
pulisher
Jul 21, 2025

What analysts say about BioCryst Pharmaceuticals Inc. stockFree Stock Selection - Autocar Professional

Jul 21, 2025
pulisher
Jul 21, 2025

BioCryst: ORLADEYO Powers Profitability Amidst Rising HAE Competition (NASDAQ:BCRX) - Seeking Alpha

Jul 21, 2025
pulisher
Jul 21, 2025

BioCryst Pharmaceuticals to Announce Q2 2025 Financial Results and Host Conference Call on August 4, 2025 - Quiver Quantitative

Jul 21, 2025
pulisher
Jul 21, 2025

BioCryst to Report Second Quarter 2025 Financial Results on August 4 - GlobeNewswire

Jul 21, 2025
pulisher
Jul 20, 2025

BioCryst Pharmaceuticals Inc. Stock Analysis and ForecastFree Wealth Management Insights - PrintWeekIndia

Jul 20, 2025
pulisher
Jul 20, 2025

What drives BioCryst Pharmaceuticals Inc. stock priceFree Capital Efficiency Planning - Autocar Professional

Jul 20, 2025
pulisher
Jul 20, 2025

How To Trade (BCRX) - news.stocktradersdaily.com

Jul 20, 2025
pulisher
Jul 18, 2025

BioCryst appoints Babar Ghias as CFO - MSN

Jul 18, 2025
pulisher
Jul 18, 2025

Will BioCryst Pharmaceuticals Inc. stock benefit from AI tech trendsCarefully Curated High Return Stocks - beatles.ru

Jul 18, 2025
pulisher
Jul 15, 2025

AscellaHealth’s Patient-Focused Approach is Best-in-Class Model for Distribution of Rare Disease Therapies - GlobeNewswire Inc.

Jul 15, 2025
pulisher
Jul 14, 2025

Zacks.com featured highlights ASR, INSW, BCRX, ASC and RRGB - The Globe and Mail

Jul 14, 2025
pulisher
Jul 13, 2025

RBC Capital Maintained a Buy on BioCryst Pharmaceutical (BCRX), Sets a PT of $13 - MSN

Jul 13, 2025
pulisher
Jul 10, 2025

BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit - GlobeNewswire

Jul 10, 2025
pulisher
Jul 09, 2025

BioCryst Unveils Groundbreaking Research on HAE Treatment Burden in Young Patients Under 12 - Stock Titan

Jul 09, 2025
pulisher
Jul 08, 2025

Island Pharmaceuticals announces purchase of Galidesivir antiviral program from Biocryst Pharmaceuticals - MarketScreener

Jul 08, 2025
pulisher
Jul 08, 2025

Island Pharmaceuticals acquires BioCryst’s Galidesivir - grafa.com

Jul 08, 2025
pulisher
Jul 08, 2025

BioCryst Pharmaceuticals appoints Babar Ghias as CFO By Investing.com - Investing.com South Africa

Jul 08, 2025
pulisher
Jul 08, 2025

BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development - GlobeNewswire

Jul 08, 2025
pulisher
Jul 08, 2025

Island Pharmaceuticals Acquires Galidesivir Antiviral Program from BioCryst Pharmaceuticals - AInvest

Jul 08, 2025
pulisher
Jul 07, 2025

CFO changes at Biocryst, Xenon, Century, Pyxis - biocentury.com

Jul 07, 2025
pulisher
Jul 07, 2025

Missed PDUFA history as Kalvista wins FDA approval for HAE - BioWorld MedTech

Jul 07, 2025
pulisher
Jul 07, 2025

Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year? - Yahoo

Jul 07, 2025
pulisher
Jul 07, 2025

BioCryst Pharmaceuticals (BCRX) Appoints New CFO, Babar Ghias - GuruFocus

Jul 07, 2025
pulisher
Jul 07, 2025

BioCryst Pharmaceuticals Appoints Babar Ghias as Chief Financial Officer and Head of Corporate Development - Quiver Quantitative

Jul 07, 2025
pulisher
Jul 07, 2025

BioCryst Pharmaceuticals appoints Babar Ghias as CFO - Investing.com

Jul 07, 2025
pulisher
Jul 07, 2025

BioCryst Taps Dealmaking Powerhouse as New CFO: $80B Transaction Expert to Drive Growth Strategy - Stock Titan

Jul 07, 2025
pulisher
Jul 07, 2025

BioCryst Pharmaceuticals shares rise 1.37% after-hours following the appointment of Babar Ghias as CFO. - AInvest

Jul 07, 2025
pulisher
Jul 06, 2025

BioCryst Appoints Babar Ghias Chief Financial Officer and Head o - GuruFocus

Jul 06, 2025
pulisher
Jul 06, 2025

BioCryst Pharmaceuticals Sells European ORLADEYO Business for Up to $264M - Insider Monkey

Jul 06, 2025
pulisher
Jul 05, 2025

10 Best High Short Interest Stocks With Huge Upside Potential - Insider Monkey

Jul 05, 2025
pulisher
Jul 03, 2025

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jul 03, 2025
pulisher
Jul 03, 2025

BioCryst Expands Team with 57,000 Share RSU Package: Latest Details on New Hiring Spree - Stock Titan

Jul 03, 2025
pulisher
Jul 01, 2025

BioCryst Pharma (BCRX) Receives Boost with Increased Price Target | BCRX Stock News - GuruFocus

Jul 01, 2025
pulisher
Jun 30, 2025

BioCryst Pharma (BCRX) Maintains Outperform Rating and $13 Price Target | BCRX Stock News - GuruFocus

Jun 30, 2025
pulisher
Jun 30, 2025

BCRX Stock Rating and Price Target Update by Wedbush | BCRX Stoc - GuruFocus

Jun 30, 2025
pulisher
Jun 29, 2025

BioCryst Pharma Sells European Business for Rare Disease Drug in $250M Deal - MedCity News

Jun 29, 2025
pulisher
Jun 28, 2025

BioCryst to sell European Orladeyo business for up to $264M - MSN

Jun 28, 2025
pulisher
Jun 27, 2025

BioCryst Pharmaceuticals (BCRX) Receives Reiterated Buy Rating from Needham | BCRX Stock News - GuruFocus

Jun 27, 2025
$71.56
price up icon 1.97%
$14.68
price down icon 0.68%
$8.90
price up icon 0.23%
drug_manufacturers_specialty_generic RDY
$14.55
price up icon 0.48%
$131.83
price down icon 0.14%
$293.12
price up icon 0.38%
자본화:     |  볼륨(24시간):